At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Blinatumomabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
In Brief
A Phase 2 clinical trial evaluating Blinatumomab for Diffuse Large B-cell Lymphoma. Completed, enrolled 25 participants across 6 sites.
Detailed Summary
The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab is effective and safe in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedDec 2012
Primary CompletionJul 2014
Study CompletionSep 2015
TodayJul 2026
First PostedDec 5, 2012
Enrollment StartJul 1, 2012
Primary CompletionJul 1, 2014
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.6 years ago
Interventions
Blinatumomabdrug
Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.